Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome

Nutrition Research

Volumn 30, Issue 10, 2010, Pages 678-688

  Christmas, David M ^a   Badawy, Abdulla A B ^b   Hince, Dana ^c   Davies, Simon J C ^a   Probert, Christopher ^a   Creed, Tom ^d   Smithson, John ^d   Afzal, Muhammad ^e   Nutt, David J ^f   Potokar, John P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CARDIFF METROPOLITAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d BRISTOL ROYAL INFIRMARY   (United Kingdom)

^e PRINCESS ROYAL HOSPITAL   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Human; IBS; Kynurenine; Serotonin; Tryptophan; Tryptophan 2,3 dioxygenase

Indexed keywords

KYNURENINE; SEROTONIN; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIET THERAPY; FEMALE; HUMAN; IRRITABLE COLON; MALE; MOOD DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SYMPTOM; TRYPTOPHAN METABOLISM;

ADULT; AFFECT; AMINO ACIDS, NEUTRAL; CASE-CONTROL STUDIES; DAIRY PRODUCTS; DIARRHEA; DIET; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; KYNURENINE; MALE; MIDDLE AGED; OXIDATION-REDUCTION; SEROTONIN; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 78149241395     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2010.09.009     Document Type: Article

References (85)

1. Muller-Lissner S.A., Bollani S., Brummer R.J., Coremans G., Dapoigny M., Marshall J.K., et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 2001, 64(3):200-204.
2. Wells N.E., Hahn B.A., Whorwell P.J. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997, 11(6):1019-1030.
3. Hahn B.A., Yan S., Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999, 60(1):77-81.
4. Drossman D.A., Li Z., Andruzzi E., Temple R.D., Talley N.J., Thompson W.G., et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993, 38(9):1569-1580.
5. Talley N.J., Spiller R. Irritable bowel syndrome: a little understood organic bowel disease?. Lancet 2002, 360(9332):555-564.
6. Whitehead W.E., Palsson O., Jones K.R. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?. Gastroenterology 2002, 122(4):1140-1156.
7. Dinan T.G., Quigley E.M., Ahmed S.M., Scully P., O'Brien S., O'Mahony L., et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?. Gastroenterology 2006, 130(2):304-311.
8. Kilkens T.O., Honig A., van Nieuwenhoven M.A., Riedel W.J., Brummer R.J. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut 2004, 53(12):1794-1800.
9. Mayer E.A., Berman S., Derbyshire S.W., Suyenobu B., Chang L., Fitzgerald L., et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002, 16(7):1357-1366.
10. Jarcho J.M., Chang L., Berman M., Suyenobu B., Naliboff B.D., Lieberman M.D., et al. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. Aliment Pharmacol Ther 2008, 28(3):344-352.
11. Cowen P.J. Serotonin and depression: pathophysiological mechanism or marketing myth?. Trends Pharmacol Sci 2008, 29(9):433-436.
12. Jouvet M. Sleep and serotonin: an unfinished story. Neuropsychopharmacology 1999, 21(2 Suppl):24S-27S.
13. Bell C., Forshall S., Adrover M., Nash J., Hood S., Argyropoulos S., et al. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 2002, 16(1):5-14.
14. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R., et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005, 19(6):567-596.
15. Anderson I.M., Ferrier I.N., Baldwin R.C., Cowen P.J., Howard L., Lewis G., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008, 22(4):343-396.
16. Gershon M.D., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132(1):397-414.
17. McLean P.G., Borman R.A., Lee K. 5-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci 2007, 30(1):9-13.
18. Gershon M.D. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999, 13(Suppl 2):15-30.
19. Camilleri M. Serotonergic modulation of visceral sensation: lower gut. Gut 2002, 51(Suppl 1):i81-i86.
20. Tack J., Sarnelli G. Serotonergic modulation of visceral sensation: upper gastrointestinal tract. Gut 2002, 51(Suppl 1):i77-i80.
21. Farthing M.J. Enterotoxins and the enteric nervous system-a fatal attraction. Int J Med Microbiol 2000, 290(4-5):491-496.
22. Aursnes I., Gjertsen M.K. Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Pharmacoepidemiol Drug Saf 2008, 17(7):707-713.
23. Atkinson W., Lockhart S., Whorwell P.J., Keevil B., Houghton L.A. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006, 130(1):34-43.
24. Lordal M., Wallen H., Hjemdahl P., Beck O., Hellstrom P.M. Concentration-dependent stimulation of intestinal phase III of migrating motor complex by circulating serotonin in humans. Clin Sci (Lond) 1998, 94(6):663-670.
25. Camilleri M., Mayer E.A., Drossman D.A., Heath A., Dukes G.E., McSorley D., et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999, 13(9):1149-1159.
26. Maxton D.G., Morris J., Whorwell P.J. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?. Aliment Pharmacol Ther 1996, 10(4):595-599.
27. Dunlop S.P., Jenkins D., Spiller R.C. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003, 98(7):1578-1583.
28. Rose W.C., Haines W.J., Warner D.T. The amino acid requirement of man. J Biol Chem 1950, 206:421-430.
29. Shaw K., Turner J., Del M.C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002, (1):CD003198.
30. Bell C.J., Hood S.D., Nutt D.J. Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J Psychiatry 2005, 39(7):565-574.
31. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990, 47(5):411-418.
32. Shufflebotham J., Hood S., Hendry J., Hince D.A., Morris K., Nutt D., et al. Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. Am J Gastroenterol 2006, 101(11):2582-2587.
33. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002, 1(8):609-620.
34. Ruddick J.P., Evans A.K., Nutt D.J., Lightman S.L., Rook G.A., Lowry C.A. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med 2006, 8(20):1-27.
35. Badawy A.A. Tryptophan metabolism in alcoholism. Nutr Res Rev 2002, 15(1):123-152.
36. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991, 5(11):2516-2522.
37. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., Der M., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115(Pt 5):1249-1273.
38. Thomas S.R., Stocker R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999, 4(5):199-220.
39. Fitzgerald P., Cassidy E.M., Clarke G., Scully P., Barry S., Quigley Eamonn M.M., et al. Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol Motil 2008, 20(12):1291-1297.
40. Clarke G., Fitzgerald P., Cryan J.F., Cassidy E.M., Quigley E.M., Dinan T.G. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol 2009, 9:6.
41. Delgado P.L., Charney D.S., Price L.H., Landis H., Heninger G.R. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci 1989, 45(24):2323-2332.
42. Fernstrom J.D., Wurtman R.J., Hammarstrom-Wiklund B., Rand W.M., Munro H.N., Davidson C.S. Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: effect of dietary protein intake. Am J Clin Nutr 1979, 32(9):1912-1922.
43. Sainio E.L., Pulkki K., Young S.N. l-Tryptophan: biochemical, nutritional and pharmacological aspects. Amino Acids 1996, 10(1):21-47.
44. Niec A.M., Frankum B., Talley N.J. Are adverse food reactions linked to irritable bowel syndrome?. Am J Gastroenterol 1998, 93(11):2184-2190.
45. Talley N.J., Zinsmeister A.R., Melton L.J. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995, 142(1):76-83.
46. Dougherty D.M., Marsh-Richard D.M., Mathias C.W., Hood A.J., Addicott M.A., Moeller F.G., et al. Comparison of 50- and 100-g l-tryptophan depletion and loading formulations for altering 5-HT synthesis: pharmacokinetics, side effects, and mood states. Psychopharmacology (Berl) 2008, 198(3):431-445.
47. Manning A.P., Thompson W.G., Heaton K.W., Morris A.F. Towards positive diagnosis of the irritable bowel. Br Med J 1978, 2(6138):653-654.
48. Badawy A.A., Morgan C.J., Turner J.A. Application of the Phenomenex EZ:faasttrade mark amino acid analysis kit for rapid gas-chromatographic determination of concentrations of plasma tryptophan and its brain uptake competitors. Amino Acids 2008, 34(4):587-596.
49. Bloxam D.L., Warren W.H. Error in the determination of tryptophan by the method of Denkla and Dewey. A revised procedure. Anal Biochem 1974, 60(2):621-625.
50. Denckla W.D., Dewey H.K. The determination of tryptophan in plasma, liver, and urine. J Lab Clin Med 1967, 69(1):160-169.
51. Badawy A.A., Evans M. Animal liver tryptophan pyrrolases: absence of apoenzyme and of hormonal induction mechanism from species sensitive to tryptophan toxicity. Biochem J 1976, 158(1):79-88.
52. Badawy A.A., Doughrty D.M., Marsh-Richard D.M., Steptoe A. Activation of liver tryptophan pyrrolase mediates the decrease in tryptophan availability to the brain after acute alcohol consumption by normal subjects. Alcohol Alcohol 2009, 44(3):267-271.
53. Morgan C.J., Badawy A.A. Effects of storage on binding and stability of tryptophan in human serum. Ann Clin Biochem 1994, 31(Pt 2):190-192.
54. Gift A.G. Visual analogue scales: measurement of subjective phenomena. Nurs Res 1989, 38(5):286-288.
55. Lovibond S.H., Lovibond P.F. Manual for the Depression Anxiety Stress Scales 1995, Psychology Foundation, Sydney. 2nd. Ed.
56. Crawford J.R., Henry J.D. The Depression Anxiety Stress Scales (DASS): normative data and latent structure in a large non-clinical sample. Br J Clin Psychol 2003, 42(Pt 2):111-131.
57. Talley N.J., Boyce P.M., Owen B.K., Newman P., Paterson K.J. Initial validation of a bowel symptom questionnaire and measurement of chronic gastrointestinal symptoms in Australians. Aust N Z J Med 1995, 25(4):302-308.
58. Badawy A.B. Plasma free tryptophan revisited: what you need to know and do before measuring it. J Psychopharmacol 2009.
59. Shufflebotham J., Wetherell M.A., Hince D., Hood S., Lightman S., Nutt D., et al. Women with diarrhoea-predominant irritable bowel syndrome show an increased pressure response to 35% carbon dioxide stress challenge. Stress 2009, 12(1):30-36.
60. Young S.N., Sourkes T.L. Tryptophan catabolism by tryptophan pyrrolase in rat liver. The effect of tryptophan loads and changes in tryptophan pyrrolase activity. J Biol Chem 1975, 250(13):5009-5014.
61. Chen Y., Guillemin G.J. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009, 2:1-19.
62. Badawy A.A., Morgan C.J., Turner T.A., Dougherty D.M., Marsh D.M., Mathias C.W., et al. Assessment of the kynurenine pathway in humans: I. Normal plasma values, ethnic differences and their clinical implications. Int Congr Series 2007, 1304:335-343.
63. Bender D.A. Biochemistry of tryptophan in health and disease. Mol Aspects Med 1983, 6(2):101-197.
64. Wollny T., Rydzewska G., Pawlak D., Turecka-Kulesza E., Buczko W., Kaswewicz W. Kynurenine pathway metabolites in serum of patients with irritable bowel syndrome - possible role in the mechanism of visceral pain. Gastroenterol Pol 2006, 13:159-162.
65. Pfefferkorn E.R., Rebhun S., Eckel M. Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts. J Interferon Res 1986, 6(3):267-279.
66. Werner E.R., Fuchs D., Hausen A., Jaeger H., Reibnegger G., Werner-Felmayer G., et al. Tryptophan degradation in patients infected by human immunodeficiency virus. Biol Chem Hoppe Seyler 1988, 369(5):337-340.
67. Fuchs D., Moller A.A., Reibnegger G., Stockle E., Werner E.R., Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990, 3(9):873-876.
68. Fuchs D., Forsman A., Hagberg L., Larsson M., Norkrans G., Reibnegger G., et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res 1990, 10(6):599-603.
69. Burns G.A., Stephens K.E. Expression of mRNA for the N-methyl-d-aspartate (NMDAR1) receptor and vasoactive intestinal polypeptide (VIP) co-exist in enteric neurons of the rat. J Auton Nerv Syst 1995, 55(3):207-210.
70. Liu M.T., Rothstein J.D., Gershon M.D., Kirchgessner A.L. Glutamatergic enteric neurons. J Neurosci 1997, 17(12):4764-4784.
71. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993, 45(3):309-379.
72. Kaszaki J., Palasthy Z., Erczes D., Racz A., Torday C., Varga G., et al. Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterol Motil 2008, 20(1):53-62.
73. Kuc D., Zgrajka W., Parada-Turska J., Urbanik-Sypniewska T., Turski W.A. Micromolar concentration of kynurenic acid in rat small intestine. Amino Acids 2008, 35(2):503-505.
74. Paluszkiewicz P., Zgrajka W., Saran T., Schabowski J., Piedra J.L., Fedkiv O., et al. High concentration of kynurenic acid in bile and pancreatic juice. Amino Acids 2009, 37(4):637-641.
75. Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis. [WO/2008/087461]. 2008. World Intellectual Property Organization. Ref Type: Patent.
76. Badawy A.A., Morgan C.J., Davis N.R., Dacey A. High-fat diets increase tryptophan availability to the brain: importance of choice of the control diet. Biochem J 1984, 217(3):863-864.
77. Bountziouka V., Polychronopoulos E., Zeimbekis A., Papavenetiou E., Ladoukaki E., Papairakleous N., et al. Long-term fish intake is associated with less severe depressive symptoms among elderly men and women: the MEDIS (MEDiterranean ISlands Elderly) epidemiological study. J Aging Health 2009, 21(6):864-880.
78. Astorg P., Couthouis A., Bertrais S., Arnault N., Meneton P., Guesnet P., et al. Association of fish and long-chain n-3 polyunsaturated fatty acid intakes with the occurrence of depressive episodes in middle-aged French men and women. Prostaglandins Leukot Essent Fatty Acids 2008, 78(3):171-182.
79. Chuang H.T., Mansell C., Patten S.B. Lifestyle characteristics of psychiatric outpatients. Can J Psychiatry 2008, 53(4):260-266.
80. Dainese R., Galliani E.A., De Lazzari F., Di L., Naccarato R. Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients. Am J Gastroenterol 1999, 94(7):1892-1897.
81. Ragnarsson G., Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998, 10(5):415-421.
82. Rogers J., Raimundo A.H., Misiewicz J.J. Cephalic phase of colonic pressure response to food. Gut 1993, 34(4):537-543.
83. Serra J., Salvioli B., Azpiroz F., Malagelada J.R. Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology 2002, 123(3):700-706.
84. Rao S.S., Welcher K., Zimmerman B., Stumbo P. Is coffee a colonic stimulant?. Eur J Gastroenterol Hepatol 1998, 10(2):113-118.
85. Carretti N., Florio P., Bertolin A., Costa C.V., Allegri G., Zilli G. Serum fluctuations of total and free tryptophan levels during the menstrual cycle are related to gonadotrophins and reflect brain serotonin utilization. Hum Reprod 2005, 20(6):1548-1553.